Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,131.09 +1,107.80 (+1.65%) CMC Crypto 200
1,375.65 +45.04 (+3.39%)
CollPlant Biotechnologies Ltd. (CLGN)
After hours:
- PR Newswire
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks. In addition, CollPlant announced additiona
- Simply Wall St.
CollPlant Biotechnologies First Quarter 2024 Earnings: Misses Expectations
CollPlant Biotechnologies ( NASDAQ:CLGN ) First Quarter 2024 Results Key Financial Results Revenue: US$98.0k (down 77...
- PR Newswire
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.
